Jazz Pharmaceuticals PLC $JAZZ Holdings Lifted by Sei Investments Co.

Sei Investments Co. raised its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 33.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 147,270 shares of the specialty pharmaceutical company’s stock after acquiring an additional 36,870 shares during the quarter. Sei Investments Co.’s holdings in Jazz Pharmaceuticals were worth $27,844,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Lido Advisors LLC bought a new position in Jazz Pharmaceuticals in the 1st quarter worth approximately $237,000. Globeflex Capital L P increased its position in Jazz Pharmaceuticals by 130.8% in the 1st quarter. Globeflex Capital L P now owns 10,594 shares of the specialty pharmaceutical company’s stock valued at $2,003,000 after acquiring an additional 6,003 shares during the period. State of Wyoming bought a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $417,000. First Trust Advisors LP raised its stake in Jazz Pharmaceuticals by 108.0% during the 1st quarter. First Trust Advisors LP now owns 91,302 shares of the specialty pharmaceutical company’s stock valued at $17,261,000 after acquiring an additional 47,402 shares in the last quarter. Finally, Westpac Banking Corp acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth $51,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on JAZZ shares. Leerink Partners raised their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. TD Cowen increased their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Barclays upped their price target on shares of Jazz Pharmaceuticals from $253.00 to $260.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Finally, Wells Fargo & Company increased their price objective on shares of Jazz Pharmaceuticals from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $259.06.

Jazz Pharmaceuticals Trading Up 0.6%

Shares of Jazz Pharmaceuticals stock opened at $255.43 on Tuesday. The business has a fifty day simple moving average of $237.89 and a 200-day simple moving average of $204.06. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $257.00. The firm has a market cap of $16.05 billion, a price-to-earnings ratio of -12,765.12, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. On average, equities analysts forecast that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the sale, the director directly owned 366,682 shares of the company’s stock, valued at $88,176,020.54. This represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 13,098 shares of company stock worth $3,131,906. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.